SecBot SecBot

BBNX

Beta Bionics, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001674632 Healthcare & Medical Devices
$21.53 +1.02 (+4.97%)
Oct 27 4:00 PM ET · prev $20.51
Market cap
$1.0B
Small cap
Consensus
Buy
74% Buy or better · 19 analysts
Median target
🔒 Subscribers only
1 year
−9.3%
from $23.75 · Oct 27
30 days
+4.9%
from $20.52
52-week range
$8.86–31.99
−33% from high · low Apr 10
Avg volume 20D
991.6K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$3.9M
0 buyers · 7 sellers · since Feb 27
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 12 reports · 90 days
Balance 6 bearish · 1 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/12
Strongest BULLISH Beta Bionics disclosed an FDA approval for its iLet bionic pancreas system and related regulatory updates…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • R Apr 21 Beta Bionics reported strong Q1 2026 revenue growth of 57% year-over…
  • S May 21 to May 22 2 days of insider sells: $41.0K by 2 insiders, avg $10.26
  • S Jun 2 to Jun 4 2 days of insider sells: $515.2K by 6 insiders, avg $12.70
  • S Jun 24 to Jun 29 3 days of insider sells: $210.4K by 3 insiders, avg $16.61
  • S Sep 2 to Sep 22 6 days of insider sells: $3.0M by 6 insiders, avg $19.24
  • X Sep 30 Short interest falls 43.0% to 6.05M
  • A Oct 12 Jefferies initiates
  • E Oct 16 M&A: Beta Bionics (BBNX) Alert: Securities Class Action Filed,…

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $3.9M.

  • InstitutionsMIXED

    Q2 2026: 17 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    14 of 19 rate it Buy or better.

  • TrendRANGE

    12% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
RTW INVESTMENTS, LPTRIM1,500,000$23.5M
BALYASNY ASSET MANAGEMENT L.P.ADD855,682$13.4M
JPMORGAN CHASE & CODOUBLED703,356$12.0M
FARALLON CAPITAL MANAGEMENT, L.L.C.NEAR_EXIT595,000$9.3M
BANK OF AMERICA CORP /DE/DOUBLED546,650$8.6M
GOLDMAN SACHS GROUP INCDOUBLED537,105$8.4M
Trexquant Investment LPDOUBLED494,435$7.7M
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDTRIM409,300$6.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 74% rate it Buy or better
Strong Buy6Buy8Hold5Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 12, 2026Jefferies
INITIATE
INITIATEBuy
Sep 24, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Sep 23, 2026Wells Fargo
INITIATE
INITIATEOverweight
Sep 15, 2026B of A Securities
MAINTAIN
MAINTAINNeutral
Sep 15, 2026Truist Securities
REITERATE
REITERATEBuy
Sep 15, 2026Baird
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$3.9M
sold · 7 insiders
DateInsiderTypeValue
Oct 14, 2026
Hopman Mark
Chief Commercial Officer
SELL$13.4K
Oct 1, 2026
Hopman Mark
Chief Commercial Officer
SELL$7.0K
Sep 22, 2026
Jones Christy
Director
SELL$147.9K
Sep 16, 2026
Hopman Mark
Chief Commercial Officer
SELL$619.6K
Sep 16, 2026
Mensinger Mike
Chief Product Officer
SELL$58.3K
Sep 14, 2026
Hopman Mark
Chief Commercial Officer
SELL$12.0K
Sep 9, 2026
Hopman Mark
Chief Commercial Officer
SELL$680.7K
Sep 9, 2026
Hopman Mark
Chief Commercial Officer
SELL$664.6K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.44-$0.52–-$0.40+13.7%$30.2M
Current FY-$1.88-$2.06–-$1.61+0.8%$124.4M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 Other
🔒 Fresh data, subscribers only
Oct 14, 2026 Insider
Hopman Mark sold 775 shares
Chief Commercial Officer @ $17.35 ($13.4K)
Oct 7, 2026 SEC
T. Rowe Price Associates, Inc. filed a Schedule 13G disclosing a 16.6% passive stake in Beta Bionics, Inc. as of…
SC 13G — Impact 4/10
Oct 1, 2026 Insider
Hopman Mark sold 370 shares
Chief Commercial Officer @ $18.96 ($7.0K)
Sep 23, 2026 SEC
Three Beta Bionics insiders, including the Chief Commercial Officer, sold a total of $826K in shares over a one-week…
CLUSTER — Impact 4/10
Sep 22, 2026 Insider
Jones Christy sold 6,430 shares
Director @ $23.00 ($147.9K)
Sep 18, 2026 SEC
Five Beta Bionics insiders, including the CEO, CFO, and Chief Commercial Officer, sold a total of $1.09M in…
CLUSTER — Impact 5/10
Sep 17, 2026 Press
Beta Bionics closed a $172.5M underwritten public offering of common stock and pre-funded warrants, including full…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Press release
🔒 Fresh data, subscribers only
Oct 27, 2026
Earnings date
🔒 Fresh data, subscribers only
Oct 26, 2026
Press release
BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
SAN FRANCISCO, Oct. 26, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ: BBNX) faces a securities class action, which seeks to represent investors…
Oct 24, 2026
Press release
BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
NEW YORK, Oct. 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics…
Oct 23, 2026
Press release
BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action
SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class…

SecBot reports

17 filings · 5 press releases · 3 bullish · 4 bearish · 10 neutral
All BBNX filing & press-release reports (22)